Subtotal $0.00
Shop Now
Tesamorelin vs sermorelin is a comparison of two synthetic versions of growth hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. Their regulatory positions are very different. Tesamorelin is an FDA-approved prescription drug, sold as Egrifta, for one narrow use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. Sermorelin was approved in the 1990s as Geref, but its maker discontinued it and the FDA withdrew the approvals in 2009; no approved sermorelin product is marketed today. Neither drug is approved for anti-aging, muscle building or general weight loss. Two peptides often compared with them, ipamorelin and CJC-1295, have never been FDA-approved.
Peptide Labs does not sell tesamorelin, sermorelin, ipamorelin, CJC-1295 or any growth hormone-related peptide. This article is general information, not medical advice. For the wider class, see our guide to growth hormone peptides.
Key Takeaways
- Tesamorelin and sermorelin are both GHRH analogs; tesamorelin is the full 44-amino-acid chain with an added fatty group, sermorelin the first 29 amino acids.
- Tesamorelin (Egrifta) has been FDA-approved since 2010, only for excess abdominal fat in adults with HIV and lipodystrophy.
- Sermorelin (Geref) approvals were withdrawn in 2009 at the maker's request; the FDA later said this was not for safety or effectiveness reasons.
- Ipamorelin works through a different receptor, the ghrelin receptor, and has never been approved.
- CJC-1295 has never been approved; a 2006 phase 2 trial was halted after a participant died.
- All four are prohibited in sport under the WADA 2026 Prohibited List.
Tesamorelin vs sermorelin at a glance
Whether you search sermorelin vs tesamorelin or tesamorelin vs sermorelin, the answer starts with regulatory status. The table puts both, and the two peptides most often compared with them, side by side. Status reflects the U.S. position in September 2026.
| Tesamorelin | Sermorelin | Ipamorelin | CJC-1295 | |
|---|---|---|---|---|
| What it is | Full 44-amino-acid GHRH with a hexenoyl group | First 29 amino acids of GHRH | Five-amino-acid ghrelin mimetic | Modified GHRH(1-29) with an albumin-binding linker (DAC) |
| Receptor | GHRH receptor | GHRH receptor | Ghrelin (growth hormone secretagogue) receptor | GHRH receptor |
| FDA status | Approved prescription drug (Egrifta) | Formerly approved (Geref); discontinued | Never approved | Never approved |
| Approved use | Excess abdominal fat in adults with HIV and lipodystrophy | None today | None | None |
| Main human evidence | Two phase 3 trials | 1990s pediatric and diagnostic studies | One phase 2 trial | Small hormone-level studies |
| WADA 2026 list | S2 (prohibited) | S2 (prohibited) | S2 (prohibited) | S2 (prohibited) |
How GHRH analogs and ghrelin mimetics work
Growth hormone release is controlled by the hypothalamus. It sends GHRH to the pituitary gland, which releases growth hormone; growth hormone then signals the liver and other tissues to make insulin-like growth factor 1 (IGF-1). Drugs that act on this system depend on a pituitary gland that can make growth hormone, which is why the tesamorelin label rules out people whose hypothalamic-pituitary system has been disrupted by surgery, radiation or head injury.
Tesamorelin
According to the Egrifta WR label, tesamorelin consists of the complete 44-amino-acid sequence of human GHRH with a hexenoyl group, a short six-carbon chain, attached at one end. See our tesamorelin profile.
Sermorelin
Sermorelin copies only the first 29 amino acids of GHRH, the section that carries its biological activity, with no added chain. See our sermorelin profile.
Ipamorelin and CJC-1295
Ipamorelin mimics ghrelin, a hormone made mainly in the stomach, at the growth hormone secretagogue receptor. CJC-1295 is a GHRH(1-29) chain with four amino acids swapped and a linker, called DAC, that binds it to albumin in the blood; its estimated half-life in 2006 studies was about 6 to 8 days.
Tesamorelin: an approved drug for one narrow use
The FDA first approved tesamorelin as Egrifta on November 10, 2010. It was later sold as a newer formulation, Egrifta SV, and in March 2025 the FDA approved Egrifta WR, which its maker, Theratechnologies, intends as the replacement. The label states that Egrifta WR and Egrifta SV are not substitutable for each other.
Approval rested on two randomized, double-blind, placebo-controlled trials in adults with HIV, lipodystrophy and excess abdominal fat, with 412 and 404 participants. The main measure was the change in visceral fat, the deep abdominal fat around the organs, on CT scans after 26 weeks. The label adds two limits: tesamorelin is not indicated for weight loss because its effect on weight is neutral, and its long-term cardiovascular safety has not been established.
The label lists who should not use it: people with a disrupted hypothalamic-pituitary system, people with active cancer, people allergic to tesamorelin, and pregnant women. Its warnings cover possible tumor risk, raised IGF-1 with unknown long-term effects, fluid retention, glucose intolerance or diabetes, allergic reactions (in 4% of trial participants) and possible increased risk of death in critical illness. The most common side effects were joint pain, redness and itching where the drug was given, pain in the arms or legs, swelling and muscle pain.
Sermorelin: approved, then discontinued
Serono, later EMD Serono, won FDA approval for two Geref products: a diagnostic test of the pituitary gland in December 1990, and a product for children with idiopathic growth hormone deficiency in September 1997. The company discontinued both and asked the FDA to withdraw the approvals, which took effect on June 18, 2009. In a Federal Register notice published March 4, 2013, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness, which means a generic version could in principle be approved if it met every other requirement. None has been.
The evidence base is old and small. A 1999 review in BioDrugs found limited data on faster growth in some children, with smaller gains than growth hormone itself for some regimens; brief facial flushing and pain where it was given were the most common side effects. It was never approved for adults. Sermorelin offered today generally comes from compounding pharmacies, and compounded drugs are not FDA-approved or reviewed by the FDA before sale.
Ipamorelin vs sermorelin
The main difference in ipamorelin vs sermorelin is the target. Sermorelin acts on the GHRH receptor, while ipamorelin acts on the ghrelin receptor, a separate route to growth hormone release. Sermorelin once had FDA approval; ipamorelin never has. See our ipamorelin profile.
Ipamorelin’s main human test was not about growth hormone at all. A phase 2 trial published in 2014 enrolled 117 adults having bowel surgery and gave ipamorelin or placebo by IV for up to a week, to see whether it sped bowel recovery; 114 were analyzed. Median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that was not statistically significant. On October 29, 2024, the FDA’s Pharmacy Compounding Advisory Committee voted 12 to 0, with 1 abstention, against adding ipamorelin to the list of substances pharmacies may use for compounding. The FDA has cited a risk of unwanted immune reactions and a published study reporting serious adverse events, including death, with intravenous ipamorelin.
CJC-1295 vs ipamorelin
CJC-1295 vs ipamorelin compares two unapproved peptides that act on different receptors and are often sold together as a blend. We found no published trial of the two combined. Our CJC-1295 profile and CJC-1295 and ipamorelin blend profile go into more detail.
CJC-1295’s published human data are small 2006 studies in healthy adults. In two trials in adults aged 21 to 61, growth hormone levels rose 2- to 10-fold for 6 days or more and IGF-1 rose 1.5- to 3-fold. They measured hormone levels, not health outcomes. In July 2006 its developer, ConjuChem, halted a phase 2 trial in people with HIV and excess abdominal fat after a participant in Argentina died. The attending physician considered undiagnosed coronary artery disease the most likely cause, unrelated to the drug, but the study was stopped as a precaution. The compounding advisory committee voted against every form of CJC-1295 it reviewed in December 2024, and the FDA has cited serious adverse events including increased heart rate and a widening of blood vessels throughout the body.
What the evidence does and does not show
- Tesamorelin has good-quality evidence for one outcome, visceral fat in adults with HIV and lipodystrophy. That evidence does not extend to people without that condition.
- Sermorelin was studied mainly as a diagnostic test and in children with growth hormone deficiency in the 1990s. There are no large controlled trials in adults.
- Ipamorelin and CJC-1295 have one negative phase 2 trial and two short hormone-level studies between them.
- Raising growth hormone or IGF-1 in a blood test is not the same as a proven health benefit, and the long-term effects of raised IGF-1 are unknown, as the tesamorelin label itself states.
- None of the four has shown in controlled trials that it builds muscle or slows aging. Our overview of peptides marketed for muscle covers those claims.
Regulatory status in 2026
Only Egrifta products, used as labeled with a prescription, carry an FDA approval. Ipamorelin and CJC-1295 are not on the FDA’s 503A Bulks List, the list of bulk substances pharmacies may use for compounding. CJC-1295 was among the substances the FDA listed in April 2026 as no longer in Category 2 after their nominations were withdrawn; the FDA said removal does not make a substance eligible for compounding. Products labeled “for research purposes only” are not approved medicines. For the wider legal picture, read are peptides legal?
Tesamorelin, sermorelin and sport
The World Anti-Doping Agency’s 2026 Prohibited List names tesamorelin, sermorelin and CJC-1295 as GHRH analogs and ipamorelin as a growth hormone secretagogue, all under class S2. They are prohibited at all times, in and out of competition.
Frequently Asked Questions
What is the difference between tesamorelin and sermorelin?
Both are GHRH analogs. Tesamorelin is the full 44-amino-acid GHRH chain with an added fatty group and is FDA-approved as Egrifta for abdominal fat in adults with HIV and lipodystrophy. Sermorelin is the first 29 amino acids and its approvals were withdrawn in 2009.
Is sermorelin FDA-approved?
Not anymore. It was sold as Geref until EMD Serono discontinued it and the approvals were withdrawn in 2009. The FDA later determined the withdrawal was not for safety or effectiveness reasons.
Is tesamorelin approved for weight loss?
No. The Egrifta label says it is not indicated for weight loss because its effect on weight is neutral. Its only approved use is reducing excess abdominal fat in adults with HIV and lipodystrophy.
Is ipamorelin better than sermorelin?
There is no trial comparing them. They act on different receptors, sermorelin once had FDA approval, and ipamorelin has never been approved. Its one phase 2 trial did not show a significant benefit.
What is the difference between CJC-1295 and ipamorelin?
CJC-1295 is a long-acting GHRH analog that binds to albumin; ipamorelin is a short ghrelin-receptor peptide. Neither is FDA-approved, and no trial has tested them together.
Peptide Labs does not sell these compounds. This page is general information, not medical advice, and nothing here is an offer or a guide to use. If you have questions about growth hormone or a related health concern, talk to a licensed healthcare provider who knows your medical history.
Last reviewed September 2026.
Related guides: HGH Peptides vs HGH: What Growth Hormone Peptides Really Are, Peptides for Muscle Growth: What the Evidence and the FDA Say, Are Peptides Legal? How U.S. Law Treats Each Type of Peptide.